FAKTOR-OPTIONSSCHEIN - INCYTE CO. Stock

DE000SD416S6

Market Closed - Bid/Ask 15:46:36 2024-06-06 EDT			Pre-market 02:00:00
2.27 ^EUR	+4.61%		2.285	+0.66%

Current month	-5.81%
1 month	-42.96%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Incyte Completes Acquisition of Escient Pharmaceuticals	05-30	BU
Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	05-23	MT
Incyte Acquires 2 Office Buildings in Delaware	05-21	MT
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings	05-21	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-06	2.27	+4.61%
24-06-05	2.17	-1.81%
24-06-04	2.21	+1.38%
24-06-03	2.18	-9.54%
24-05-31	2.41	-4.74%

Real-time Boerse Frankfurt Warrants

Last update June 06, 2024 at 03:46 pm

More quotes

Static data

Product type	Exotische Produkte
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Société Générale
WKN	SD416S
ISIN	DE000SD416S6
Date issued	2021-03-29
Strike	79.94 $
Maturity	Unlimited
Parity	1 : 1
Emission price	8.47 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	17.82 €
Lowest since issue	0.91 €
Spread	0.01 €
Spread %	0.44%

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

58.41 USD

Average target price

72.8 USD

Spread / Average Target

+24.64%

Consensus